Allecra Theraps Drug Patent Portfolio
Allecra Theraps owns 1 orange book drug protected by 2 US patents Given below is the list of Allecra Theraps's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11124526 | Crystalline beta-lactamase inhibitor | 07 Nov, 2034 | Active |
US7687488 | 2-substituted methyl penam derivatives | 03 Dec, 2027 | Active |
Latest Legal Activities on Allecra Theraps's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Allecra Theraps.
Activity | Date | Patent Number |
---|---|---|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Jul, 2024 | US7687488 |
Email Notification
Critical
| 03 Jul, 2024 | US7687488 |
Initial letter Re: PTE Application to regulating agency | 25 Apr, 2024 | US7687488 |
Initial letter Re: PTE Application to regulating agency | 25 Apr, 2024 | US11124526 |
Requirement for information sent under 37 CFR 1.750 | 25 Apr, 2024 | US7687488 |
Payment of Maintenance Fee, 12th Year, Large Entity | 22 Sep, 2021 | US7687488 |
Patent Issue Date Used in PTA Calculation
Critical
| 21 Sep, 2021 | US11124526 |
Recordation of Patent Grant Mailed
Critical
| 21 Sep, 2021 | US11124526 |
Email Notification
Critical
| 02 Sep, 2021 | US11124526 |
Issue Notification Mailed
Critical
| 01 Sep, 2021 | US11124526 |
Application Is Considered Ready for Issue
Critical
| 18 Aug, 2021 | US11124526 |
Dispatch to FDC | 18 Aug, 2021 | US11124526 |
Issue Fee Payment Received
Critical
| 16 Aug, 2021 | US11124526 |
Issue Fee Payment Verified
Critical
| 16 Aug, 2021 | US11124526 |
Email Notification
Critical
| 17 May, 2021 | US11124526 |
Allecra Theraps's Family Patents
Allecra Theraps Drug List
Given below is the complete list of Allecra Theraps's drugs and the patents protecting them.
1. Exblifep
Exblifep is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11124526 | Crystalline beta-lactamase inhibitor |
07 Nov, 2034
(9 years from now)
| Active |
US7687488 | 2-substituted methyl penam derivatives |
03 Dec, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exblifep's drug page